Lytix Biopharma AS (6BG.F)

0.5180 +0.0570 (+12.36%) At close: 08:07AM CEST

Lytix Biopharma AS

Sandakerveien 138
Oslo 0484
Norway

https://www.lytixbiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Oystein Rekdal Ph.D.	Co-Founder & CEO	314.87k	N/A	N/A
Mr. Gjest Breistein M.Sc.	Chief Financial Officer	N/A	N/A	N/A
Dr. Gry Stensrud Ph.D.	Chief Technology Officer	N/A	N/A	1970
Dr. Baldur Sveinbjørnsson Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Ole Peter Nordby	Head of IR & Communication Manager	N/A	N/A	N/A
Jacqueline Earabino	Head of Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.

Corporate governance

Lytix Biopharma AS’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.